- Policy
- Multiple myeloma CAR-T therapeutic agent CARVYKTI, imminent
- by Lee, Hye-Kyung Mar 9, 2023 06:00am
- CARVYKTI compares self -hematopoietic stem cell transplantation (ASCT) after administration of Daratumumab, Bortezomib, Lenalidomide, and DVRD in December last year. The clinical trial was conducted. According to the industry on the 8th, the Ministry of Food and Drug Safety recently completed the safety and validation of Carvykti. If the Effi
- Policy
- Gov expands SGLT-2 diabetes drug combi benefit from April
- by Lee, Jeong-Hwan Mar 8, 2023 05:53am
- The Ministry of Health and Welfare will be the first to recognize the 3-drug combination benefit for diabetes treatment with SGLT-2 inhibition mechanism from April and expand the scope of the 2-drug combination benefit compared to the previous one. Specifically, 'Metformin + SGLT-2 inhibitor + DPP-4 inhibitor' and 'Metformin + SGLT-2 inhib
- Policy
- PVA, the higher the bill, the greater the discount rate
- by Lee, Tak-Sun Mar 8, 2023 05:52am
- The NHIS plans to increase the reduction rate of the upper limit for drugs with high claims in the PVA, and lower the reduction rate or exclude drugs with low claims. This is based on research conducted last year. The results of the research service (performance evaluation and improvement plan of PVA (researcher: Bae Seung-jin, Ewha Womans Un
- Policy
- Free vaccination of Rotarix·RotaTeq is available
- by Lee, Jeong-Hwan Mar 7, 2023 05:39am
- The Korea Centers for Disease Control and Prevention (KCDC) will start a national vaccination project for Rotavirus vaccines Rotarix and RotaTeq, which are distributed in Korea, from the 6th. From this day, infants aged 2 to 6 months who are subject to vaccination will be able to receive one of the two vaccines free of charge at nationall
- Policy
- ‘Improve rare disease designations standards for equity'
- by Lee, Jeong-Hwan Mar 7, 2023 05:38am
- The claim that Korea’s rare disease designation standards should be improved and expanded to ease the disease burden borne by patients from drug costs, etc. The request arose with the rising need to address the irrationalities in the current rare disease designation system, such as those from the unclear diagnostic criteria set due to th
- Policy
- ‘RSA may be applied to non-rare innovative new drugs'
- by Lee, Jeong-Hwan Mar 7, 2023 05:38am
- The Ministry of Health and Welfare announced it will improve its policy to allow innovative new drugs to be listed for reimbursement through the risk-sharing assessment (RSA) track even if they are not anticancer or rare disease treatments if they demonstrate a clinical effect. If allowed, it is expected that the scope of drugs that are
- Policy
- Tecentriq fails urothelial carcinoma trial but beneficial
- by Lee, Hye-Kyung Mar 6, 2023 05:56am
- Although the conditional clinical trial failed for Roche’s cancer immunotherapy ‘Tecentriq,’ experts in Korea decided to recognize Tecentriq’s benefit for ‘patients with locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy’ and maintain the indication as it is unethical to reorder cli
- Policy
- Full-fledged competition in the ultra-large market
- by Lee, Tak-Sun Mar 6, 2023 05:56am
- Competition among domestic pharmaceutical companies surrounding the ultra-large market is expected to intensify from April. About 20 companies are expected to receive benefits in the late-breaking drug market for Dukarb, a high blood pressure complex drug of Boryung, which four companies first entered in March, and AstraZeneca's diabetes dru
- Policy
- GC Biopharma’s Livmarli approved as first ALGS Tx in KOR
- by Lee, Hye-Kyung Mar 2, 2023 05:53am
- The Ministry of Food and Drug Safety (Minister: Yu-Kyoung Oh) announced that the ministry approved GC Biopharma’s ‘Livmarli (maralixibat chloride)’ on the 28th. Livmarli is an imported rare disease drug used to treat cholestatic pruritus in patients with Alagille syndrome who are 1 year of age and older. Alagille syndrome is a rare gen
- Policy
- Negotiations on the Brukinsa price have begun
- by Lee, Tak-Sun Feb 28, 2023 05:52am
- Crysvita and Dupixent are also negotiating drug prices. It has been found that Chinese pharmaceutical company BeiGene Korea has entered into drug price negotiations with the NHIS for Brukinsa capsules 80mg sold domestically. When the NHIS drug price negotiation is completed, the drug will be covered through a report to the Health Insurance Po
